SynRG Brings its Business to the U.S.
Synergy Research Group (SynRG) is moving its business development center to the United States. The company's new Director of Business Development will be located in North Kingstown, RI.
The company hopes that in the current situation Russia will be even more attractive in terms of clinical trials for American small and mid-sized sponsors.
“We have always emphasized that one of the strategic goals set by SynRG is enhancing of research and investment attractiveness of Russia for foreign sponsors, so business development in the USA is a natural step along this strategic line," says SynRG CEO Igor Stefanov. “We spent quite some time interviewing candidates and conversing with the finalists, and now I am happy to introduce our new Director of Business Development, Anna Ravdel."
Anna Ravdel has graduated from the University of Manchester with an MBA degree, and worked as a marketing and sales director in various international companies. Prior to joining SynRG, Anna had worked as a Director of Business Development at Evidence Clinical and Pharmaceutical Research (Russia/USA) and at a global CRO Worldwide Clinical Trials.
SynRG also has plans of opening a Ukrainian office and, probably, a virtual office in Prague, as more and more of their clients are interested in the presence from Eastern European countries to Kazakhstan on a regional level.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
